Jump to Main Contents

Home > Organization > Divisions and Independent Research Units > Group for Frontier Science > Division of Molecular Modification and Cancer Biology

Division of Molecular Modification and Cancer Biology



In 2004, we reported the functions of SMYD3, a histone methyltransferase, in human tumorigenesis in Nature Cell Biology, and this was the first report to describe how dysregulation of histone methylation contributes to human tumorigenesis at the molecular level. This article was also introduced in Nature Reviews Cancer and Nature Reviews Molecular Cell Biology, and the press release was issued in Nature Cell Biology because the report showed a novel type of target for anti-cancer therapy. Since then, we have

already reported a number of enzymes relevant to protein methylation, which are involved in human cancer, and contributes to the progress of novel field of cancer research. Dr. Hamamoto, the chief of this division, wrote an article describing our previous achievements in Nature Reviews Cancer (Hamamoto et al., Nature Reviews Cancer, 15, 110 - 124 [2015]) as the first and corresponding author. We also started a new project relevant to cancer medical AI in 2016

Past and Current Research Activities

  1. We identified three novel substrates of non-histone methylation as shown below.
    a. AKT1 methylation by histone methyltransferase SMYD3 to regulate the PI3K-AKT1 pathway
    b. Automethylation of the histone methyltransferase SUV39H2 to regulate its enzyme activity
    c. EGFR methylation by histone methyltransferase WHSC1L1 to regulate the downstream pathway
  2. We demonstrated that expression levels of the histone methyltransferase EZH2 and the immune checkpoint blockade agent PD-L1 were statistically correlated in lung cancer patients (adenocarcinoma, squamous carcinoma, small cell carcinoma). In addition, lung cancer patients with EZH2+/PD-L1+ showed poorer prognosis than those with EZH2+/PD-L1- (both recurrence-free survival and overall survival).